TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review

被引：39

作者：

Zixin, Ye ^{[1
,2
,3
,4
]}

Lulu, Chen ^{[5
,6
]}

Xiangchang, Zeng ^{[1
,2
,3
,4
]}

Qing, Fang ^{[5
]}

Binjie, Zheng ^{[1
,2
,3
,4
]}

Chunyang, Luo ^{[6
]}

Tai, Rao ^{[1
,2
,3
,4
]}

Dongsheng, Ouyang ^{[1
,2
,3
,4
,5
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China

[2] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Peoples R China

[3] Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha, Peoples R China

[4] Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[5] Hunan Key Lab Bioanal Complex Matrix Samples, Changsha, Peoples R China

[6] Affiliated Hosp Xiangnan Univ, Dept Clin Pharm, Chenzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

trimethylamine N-oxide; chronic kidney disease; gut microbiota; targeted TMAO drugs; mechanism; treatment; TRIMETHYLAMINE-N-OXIDE; FLAVIN-CONTAINING MONOOXYGENASE; L-CARNITINE; RENAL-INSUFFICIENCY; PROBIOTIC SUPPLEMENTATION; MICROBIAL-METABOLISM; SECONDARY PREVENTION; CONTRIBUTES; PROGRESSION; FMO3;

D O I：

10.3389/fphar.2022.929262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an important contributor to morbidity and mortality from non-communicable diseases. Recently, increasing focus has been put on the role of TMAO in the development and progress of chronic kidney disease. The level of TMAO in patients with chronic kidney disease is significantly increased, and a high level of TMAO deteriorates chronic kidney disease. This article describes the relationship between TMAO and chronic kidney disease and the research progress of drugs targeted TMAO, providing a reference for the development of anti-chronic kidney disease drugs targeted TMAO.

引用

页数：12

共 50 条

[41] LncRNA as potential biomarker and therapeutic target in glioma
Xu, Xun
Liang, Yuan
Gareev, Ilgiz
Liang, Yanchao
Liu, Rui
Wang, Ning
Yang, Guang
MOLECULAR BIOLOGY REPORTS, 2023, 50 (01) : 841 - 851
[42] Resistin: Potential biomarker and therapeutic target in atherosclerosis
Zhou, Li
Li, Jun-Yi
He, Ping-Ping
Yu, Xiao-Hua
Tang, Chao-Ke
CLINICA CHIMICA ACTA, 2021, 512 : 84 - 91
[43] Therapeutic Potential of Gum Arabic (Acacia senegal) in Chronic Kidney Disease Management: A Narrative Review
Alobaidi, Sami
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
[44] Proteinuria in chronic kidney disease in cats - Prognostic marker or therapeutic target?
Elliott, Jonathan
Syme, Harriet M.
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2006, 20 (05) : 1052 - 1053
[45] Fluid overload as a therapeutic target for the preservative management of chronic kidney disease
Palmer, Biff F.
Clegg, Deborah J.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (01): : 22 - 28
[46] Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease
Yujiro Kida
Bie Nga Tchao
Ikuyo Yamaguchi
Pediatric Nephrology, 2014, 29 : 333 - 342
[47] Actin cytoskeleton alterations in podocytes: a therapeutic target for chronic kidney disease
Susan J. Allison
Nature Reviews Nephrology, 2015, 11 (7) : 385 - 385
[48] Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease
Malyszko, Jolanta
Malyszko, Jacek S.
Matuszkiewicz-Rowinska, Joanna
EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (05) : 407 - 421
[49] Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?
Lee, Grace J.
Marks, Joanne
PEDIATRIC NEPHROLOGY, 2015, 30 (03) : 363 - 371
[50] Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?
Grace J. Lee
Joanne Marks
Pediatric Nephrology, 2015, 30 : 363 - 371

← 1 2 3 4 5 →